Innovation | Novartis United States of America

Media Release
Dec 07, 2015
Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL
Media Release
Dec 06, 2015
Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma
Media Release
Nov 20, 2015
Novartis Pharmaceuticals Corporation finalizes settlement agreement resolving civil suit filed by the U.S. Attorney’s Office for the Southern District of New York
Media Release
Nov 10, 2015
Novartis heart failure medicine Entresto™ substantially cuts 30-day hospital readmissions, new post-hoc analysis shows
Media Release
Nov 07, 2015
Up to 80% of ankylosing spondylitis patients treated with Cosentyx® show no spinal x-ray progression as shown in Novartis new two-year observational data
Media Release
Nov 07, 2015
Approximately 80% of psoriatic arthritis patients treated with Cosentyx® saw no progression of joint damage as shown in Novartis new two-year observational data
Media Release
Oct 29, 2015
FDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler® for patients with chronic obstructive pulmonary disease
Media Release
Oct 27, 2015
Novartis Clarification on Specialty Pharmacy Settlement in Principle Announcement
Media Release
Sep 30, 2015
Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
Media Release
Sep 27, 2015
Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
Media Release
Sep 24, 2015
Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
Media Release
Jul 24, 2015
FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer

‹ Previous page
1
…
16
17
18
19
20
21
22
…
50
› Next page